Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells - Caohuy, Hung; Eidelman, Ofer; Chen, Tinghua; Liu, Shufeng; Yang, Qingfeng; Bera, Alakesh; Walton, Nathan I.; Wang, Tony T.; Pollard, Harvey B. (Scientific reports, 2021)
Keywords: 631/154/556; 631/92/609; 692/699/1785/4039; A549 Cells; ACE2; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - metabolism; Animals; Cardiac glycosides; Cardiotonic Agents - pharmacology; Chlorocebus aethiops; COVID-19; COVID-19 - metabolism; COVID-19 Drug Treatment; Digitoxin - pharmacology; Digoxigenin; Digoxin; Digoxin - pharmacology; Glycosides; Humanities and Social Sciences; Humans; Infectivity; Lung - drug effects; Lung - metabolism; multidisciplinary; Ouabain; Ouabain - pharmacology; Protein Binding - drug effects; Proteins; SARS-CoV-2 - drug effects; SARS-CoV-2 - physiology; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - metabolism; Spike protein; Vero Cells; Virus Internalization - drug effects